GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UnicoCell Biomed Co Ltd (TPE:6794) » Definitions » Net Current Asset Value

UnicoCell Biomed Co (TPE:6794) Net Current Asset Value : NT$9.86 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is UnicoCell Biomed Co Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

UnicoCell Biomed Co's net current asset value per share for the quarter that ended in Mar. 2025 was NT$9.86.

The historical rank and industry rank for UnicoCell Biomed Co's Net Current Asset Value or its related term are showing as below:

TPE:6794' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.43   Med: 8.48   Max: 12.71
Current: 6.43

During the past 8 years, the highest Price-to-Net-Current-Asset-Value Ratio of UnicoCell Biomed Co was 12.71. The lowest was 6.43. And the median was 8.48.

TPE:6794's Price-to-Net-Current-Asset-Value is ranked worse than
65.99% of 985 companies
in the Biotechnology industry
Industry Median: 3.91 vs TPE:6794: 6.43

UnicoCell Biomed Co Net Current Asset Value Historical Data

The historical data trend for UnicoCell Biomed Co's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UnicoCell Biomed Co Net Current Asset Value Chart

UnicoCell Biomed Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Current Asset Value
Get a 7-Day Free Trial 5.38 3.38 3.72 7.49 8.54

UnicoCell Biomed Co Quarterly Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.07 9.48 9.33 8.54 9.86

Competitive Comparison of UnicoCell Biomed Co's Net Current Asset Value

For the Biotechnology subindustry, UnicoCell Biomed Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UnicoCell Biomed Co's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where UnicoCell Biomed Co's Price-to-Net-Current-Asset-Value falls into.


;
;

UnicoCell Biomed Co Net Current Asset Value Calculation

UnicoCell Biomed Co's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net Current Asset Value Per Share(A: Dec. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(592.35-93.281-0-0)/58.411
=8.54

UnicoCell Biomed Co's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2025 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(681.794-84.18-0-0)/60.611
=9.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


UnicoCell Biomed Co  (TPE:6794) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


UnicoCell Biomed Co Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of UnicoCell Biomed Co's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


UnicoCell Biomed Co Business Description

Traded in Other Exchanges
N/A
Address
Minquan East Road, 5th Floor, No. 13-20, Section 6, Neihu District, Taipei, TWN, 11494
UnicoCell Biomed Co Ltd focused on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The main business of the company includes new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D.

UnicoCell Biomed Co Headlines

No Headlines